41 patents
Utility
Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
2 Jan 24
The present disclosure provides host cells, e.g., bacterial cells, that comprise a methionine decarboxylase enzyme for the treatment of diseases and disorders associated with methionine metabolism in a subject.
Dylan Alexander Carlin, Vincent M. Isabella, Jonathan McMurry, Theodore Carlton Moore, III, Mylene Perreault, Nathan Schmidt, Mark Simon
Filed: 11 Aug 22
Utility
Bacteria engineered to treat diseases associated with hyperammonemia
19 Dec 23
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
Filed: 16 Dec 20
Utility
Bacteria Engineered to Secrete Active Proteins
19 Oct 23
Recombinant bacteria capable of producing effector molecules, which are secreted as therapeutically active polypeptides, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, cancer and/or metabolic diseases, are disclosed.
Dean Falb, Vincent M. Isabella, Paul F. Miller, Adam B. Fisher, Ning Li, Jose M. Lora
Filed: 30 Sep 21
Utility
Microorganisms engineered to reduce hyperphenylalaninemia
26 Sep 23
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
Kristin Adolfsen, Per Greisen, Isolde Callihan, Adam Lawrence, James Spoonamore, Jay Konieczka
Filed: 3 Jun 22
Utility
Recombinant Bacteria for Production of D-lactate And/or L-lactate and Uses Thereof
21 Sep 23
The present disclosure provides recombinant bacteria for production of D-lactate and/or L-lactate.
Ning Li, Anna Sokolovska, Francisco Quintana, Liliana Sanmarco
Filed: 6 Aug 21
Utility
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
15 Aug 23
Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li
Filed: 11 Jan 17
Utility
Microorganisms Programmed to Produce Immune Modulators and Anti-cancer Therapeutics In Tumor Cells
20 Jul 23
Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
Filed: 2 Aug 22
Utility
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
27 Jun 23
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
Filed: 8 Sep 16
Utility
Recombinant Bacteria Engineered to Treat Diseases Associated with Uric Acid and Methods of Use Thereof
6 Apr 23
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off.
Vincent M. Isabella, Sean Cotton, Jian-Rong Gao, Teodelinda Mirabella, Christopher George Bergeron
Filed: 25 Feb 21
Utility
Bacteria engineered to reduce hyperphenylalaninemia
4 Apr 23
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
Filed: 16 Nov 16
Utility
Bacteria Engineered to Treat Disorders In Which Oxalate Is Detrimental
23 Mar 23
The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme.
Vincent M. Isabella, David Lubkowicz, Michael James
Filed: 14 Jan 21
Utility
Recombinant Bacteria Engineered to Treat Diseases Associated with Methionine Metabolism and Methods of Use Thereof
23 Mar 23
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off.
Vincent M. Isabella, Sean Cotton
Filed: 12 Feb 21
Utility
Recombinant Bacteria Engineered to Treat Diseases Associated with Methionine Metabolism and Methods of Use Thereof
2 Mar 23
The present disclosure provides host cells, e.g., bacterial cells, that comprise a methionine decarboxylase enzyme for the treatment of diseases and disorders associated with methionine metabolism in a subject.
Dylan Alexander Carlin, Vincent M. Isabella, Jonathan McMurry, Theodore Carlton Moore, III, Mylene Perreault, Seth Ritter, Nathan Schmidt, Mark Simon
Filed: 11 Aug 22
Utility
Bacteria Engineered to Treat Diseases That Benefit from Reduced Gut Inflammation And/or Tightened Gut Mucosal Barrier
9 Feb 23
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
Filed: 8 Jun 22
Utility
Microorganisms Engineered to Reduce Hyperphenylalaninemia
17 Nov 22
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
Kristin ADOLFSEN, Per GREISEN, Isolde CALLIHAN, Adam LAWRENCE, James SPOONAMORE, Jay KONIECZKA
Filed: 3 Jun 22
Utility
Optimized Bacteria Engineered to Treat Disorders Involving the Catabolism of Leucine, Isoleucine, And/or Valine
17 Nov 22
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patients internal environment and respond by turning an engineered metabolic pathway on or off.
Ning Li, Jian-Rong Gao, Philippa Jane Reeder Morrison, Christopher George Bergeron, Dylan Alexander Carlin, Laura K. Stone, Alex C. Tucker, Patrick M. Boyle
Filed: 19 Jun 20
Utility
Biosynthesis of Enzymes for Use In Treatment of Maple Syrup Urine Disease (Msud)
3 Nov 22
Provided in this disclosure, in some embodiments, are methods and compositions for treating maple syrup urine disease (MSUD) and other conditions characterized by excessive branched-chain amino acids.
Patrick Boyle, Dylan Alexander Carlin, Rishi Jain, Ryan Putman, Laura Stone, Alex C. Tucker, Kolea Zimmerman
Filed: 19 Jun 20
Utility
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
18 Oct 22
Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
Filed: 5 Jan 18
Utility
Bacteria engineered to treat liver disease
13 Sep 22
The disclosure provides genetically engineered bacteria that are capable of reducing excess ammonia and converting ammonia and/or nitrogen into alternate byproducts.
Paul F. Miller, Vincent M. Isabella, Dean Falb, Jonathan W. Kotula, Yossi Dagon
Filed: 31 May 19
Utility
Enumeration of Genetically Engineered Microorganisms by Live Cell Counting Techniques
18 Aug 22
Genetically engineered microorganisms, e.g., genetically engineered bacteria, compositions and formulations thereof, as well as methods for characterizing, dosing, and determining the activity of the bacteria, compositions, and formulations, e.g., using a live cell counting method are disclosed.
Eugene ANTIPOV
Filed: 29 Apr 20